Showing results (41-50 of 914) with videos related to

Sort By:
Pageof 92
Therapeutic Drug Monitoring|November 6, 2024
Untangling the Exposure-Response Relationship of Allopurinol in the Setting of Chronic Kidney Disease and Diuretic Use: Implications for DosingHailemichael Z Hishe, Sophie L Stocker, Lisa K Stamp, et al.
Rheumatology (Oxford, England)|August 13, 2024
Association of rare and common genetic variants in MOCOS with inadequate response to allopurinolNiamh C Fanning, Murray Cadzow, Ruth K Topless, et al.
Rheumatology (Oxford, England)|August 15, 2018
Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trialLisa K Stamp, Peter T Chapman, Murray Barclay, et al.
Arthritis and Rheumatism|April 11, 2012
Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinolLisa K Stamp, William J Taylor, Peter B Jones, et al.
Annals of the Rheumatic Diseases|August 24, 2017
Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension studyLisa K Stamp, Peter T Chapman, Murray Barclay, et al.
The Journal of Rheumatology|December 17, 2017
Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting RequirementsLisa K Stamp, Melanie B Morillon, William J Taylor, et al.
Clinical Pharmacokinetics|July 28, 2025
The Influence of Patient Factors on the Population Pharmacokinetics of Colchicine: Implications for Safe and Effective DosingDaniel F B Wright, Hailemichael Z Hishe, Nicola Dalbeth, et al.
The Journal of Rheumatology|July 1, 2022
Long-Term Follow-up of a Randomized Controlled Trial of Allopurinol Dose Escalation to Achieve Target Serum Urate in People With GoutGeorge B Coleman, Nicola Dalbeth, Chris Frampton, et al.
Arthritis Care & Research|January 3, 2023
Changes in Tophus Composition During Urate-Lowering Therapy: A Dual-Energy Computed Tomography StudyLeanne Chen, Gregory D Gamble, Anne Horne, et al.
Pageof 92